H.C. Wainwright Thinks Enlivex Therapeutics’ Stock is Going to Recover

By Jason Carr

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Enlivex Therapeutics (ENLVResearch Report), with a price target of $22.00. The company’s shares closed last Monday at $5.60, close to its 52-week low of $3.59.

According to TipRanks.com, Selvaraju is a top 100 analyst with an average return of 38.2% and a 61.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Black Diamond Therapeutics, and Turning Point Therapeutics.

Currently, the analyst consensus on Enlivex Therapeutics is a Moderate Buy with an average price target of $22.00.

See today’s analyst top recommended stocks >>

Based on Enlivex Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $794K. In comparison, last year the company had a GAAP net loss of $2.67 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.